...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature clinical practice. Oncology >Who should receive myeloablative therapy for diffuse large B-cell lymphoma?
【24h】

Who should receive myeloablative therapy for diffuse large B-cell lymphoma?

机译：谁应该为弥漫性大B细胞淋巴瘤接受清髓治疗？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of non-Hodgkin's lymphoma (NHL). At present, first-line treatment based on the combination of the anti-CD20 monoclonal antibody, rituximab, with anthracycline-based chemotherapy regimens can cure more than half of all patients with newly-diagnosed DLBCL. Patients who relapse or fail to attain a remission after first-line therapy have a very poor prognosis even after salvage treatment with conventional chemotherapy, with only 10% of patients surviving long term. We believe that high-dose therapy and autologous hematopoietic stem cell support (autologous stem cell transplantation [ASCT]) should be the standard treatment for patients with DLBCL who have relapsed after primary therapy, and should also be considered for patients who are refractory to first-line treatment and patients with histological transformation from a 'low-grade' histology. Only patients achieving at least a partial remission (PR) after the pretransplant salvage regimen, however, are likely to benefit from this procedure.
机译：弥漫性大B细胞淋巴瘤（DLBCL）是非霍奇金淋巴瘤（NHL）的最常见侵袭性形式。目前，基于抗CD20单克隆抗体利妥昔单抗与以蒽环类为基础的化疗方案相结合的一线治疗可以治愈一半以上的新诊断DLBCL患者。一线治疗后复发或未能缓解的患者预后很差，即使采用常规化学疗法进行挽救后也是如此，只有10％的患者可以长期生存。我们认为，大剂量治疗和自体造血干细胞支持（自体干细胞移植[ASCT]）应是初治后复发的DLBCL患者的标准治疗方法，也应考虑对初次难治的患者线治疗和患者从“低级”组织学转变为组织学。但是，只有在移植前挽救方案后至少达到部分缓解（PR）的患者才有可能从该程序中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号